New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
12:26 EDTALNYAlnylam presents new pre-clinical data on RNAi therapeutics
Alnylam Pharmaceuticals announced that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemoglobinopathies at the 54th American Society of Hematology Annual Meeting being held December 8-11, 2012 in Atlanta. Alnylam scientists presented data showing that ALN-TMP, an RNAi therapeutic targeting Tmprss6, leads to disease modifying effects, including a correction in globin gene expression, in a model of ß-thalassemia. These studies were conducted in collaboration with Boston Children’s Hospital. Alnylam’s program in hemoglobinopathies comprises part of its ‘Alnylam 5x15™’ product strategy, by which the company aims to advance five programs in clinical development, including programs in advanced stages, by the end of 2015.
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
06:08 EDTALNYAlnylam 4.737M share Secondary priced at $95.00
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use